non fda approved glp 1 restricts GLP-1 ingredients in non-approved compounded drugs | FDA posted on the topic FDA's Major Action on Non-Approved

Additionally, they suppress glucagon secretion from the pancreas, further contributing to improved glycemic control

Serious Safety Concerns Associated With Saxenda Severe Gastrointestinal Motility Disorders Reported injuries include: gastroparesis (stomach paralysis) ileus (functional bowel shutdown) severe constipation chronic digestive dysfunction Related: Motility Disorders Dehydration & Kidney Injury Ongoing vomiting or reduced intake may lead to: dehydration electrolyte imbalance acute kidney injury (AKI) worsening kidney disease Related: Dehydration and Kidney Damage Gallbladder Disease Weight loss and altered bile flow may increase the risk of: gallstones gallbladder inflammation gallbladder removal surgery Related: Gallbladder Removal Pancreatitis Some patients report: severe abdominal pain elevated pancreatic enzymes hospitalization for pancreatitis Related: Pancreatitis Vision Problems / NAION Serious vision complications, including Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) , have been reported across the GLP-1 drug class

This primes your skin with antioxidant protection for the day ahead

Ozempic or Wegovy (Semaglutide) - This medication is a significant development for kidney health

His expertise spans healthcare, technology, and mineral exploration